West Pharmaceutical Services has been a quiet giant in pharmaceutical packaging, but a sharp stock split and rising analyst targets have put it back on investors’ radar, with shares currently trading near $336, fueled by strong demand for drug components and delivery systems. Here’s what the numbers and Wall Street consensus say about where WST might be headed.

4 related posts

Current Share Price: $336.39 ·
Analyst Target Price: $343.00 ·
Stock Split History: 2-for-1 split in 2021 ·
Today’s Change: +$4.55 (+1.38%)

Quick snapshot

1Current Price
2Analyst Target
3Stock Splits
4Growth Prospects

Five key figures tell the story of West Pharma’s valuation and financial health.

Metric Value Source
Current Price $336.39 MarketBeat (financial data platform)
P/E Ratio Approx. 35 West Pharma IR
Market Cap Approx. $25 billion MarketBeat (financial data platform)
Dividend Yield 0.6% Investing.com
52-Week Range $280 – $360 MarketBeat (financial data platform)
Revenue Forecast 2026 $3.22B – $3.28B Reuters
Q2 2026 Net Sales Guidance $830M – $850M PR Newswire / West Pharma
The implication: West Pharma trades at a premium P/E relative to the broader market, reflecting investor confidence in its growth trajectory, but the dividend yield remains modest.

Is West Pharmaceutical a good stock to buy?

Analyst recommendations

Key financial ratios

  • P/E ratio of ~35 suggests a growth premium.
  • Dividend yield of 0.6% is below the S&P 500 average.

Industry position

West Pharma is the leading supplier of pharmaceutical packaging components and drug delivery systems. The company’s 2026 revenue guidance of $3.22B–$3.28B aligns with analyst estimates of $3.25B (Reuters (global news agency)).

The pattern: analysts are collectively bullish, but the wide target range ($250–$400) signals that outcomes depend heavily on execution and market conditions.
Bottom line: West Pharma is a buy according to most analysts, but value investors may hesitate at the current P/E. Growth investors see upside from drug component demand; income investors will find the dividend thin.

The consensus reflects a growth premium that requires sustained execution.

What is the stock price forecast for West Pharma?

Short-term outlook

Long-term price targets

Key catalysts

  • Strong demand for drug components and delivery systems.
  • Company forecast 2026 adjusted profit above estimates (Reuters (global news agency)).

The trade-off: even a $400 target implies significant upside, but that level depends on sustained demand growth and no regulatory shocks.

Has West Pharma stock been split before?

Historical split events

  • A 2-for-1 stock split was executed in 2021 (West Pharmaceutical Services (official company investor relations)).

Impact on share price

The split did not change the company’s market cap but improved liquidity and made shares more accessible to retail investors. Post-split, the price has ranged roughly $160–$360 (adjusted).

Future split prospects

No further splits have been announced or are widely anticipated.

The catch: splits are cosmetic, but they can signal management confidence and broaden the shareholder base.

What are WST’s growth prospects?

Revenue drivers

  • Pharmaceutical components segment: a primary growth driver.
  • Diagnostic and drug delivery systems expanding.

Product pipeline

West invests in advanced packaging and delivery technologies, including prefilled syringes and high-value elastomer components.

Market expansion

  • Pharmaceutical packaging market growing due to biologics and vaccine demand.
  • West’s Q1 2026 results showed net sales of $X (see Q2 guidance).

Why this matters: West’s growth is tied to the broader pharma supply chain, which shows no signs of slowing.

What is West Pharma’s share price history?

52-week range

  • Low: $280; High: $360

All-time highs and lows

The stock reached an all-time high near $400 in 2023. The 2021 split lowered the per-share price but has since recovered.

Recent performance

Year-to-date 2026, WST is trading near the upper end of its 52-week range, reflecting positive sentiment.

The pattern: the stock shows volatility but has trended upward over the long term.

Upsides

  • Strong buy consensus from multiple analysts
  • Industry leader in pharmaceutical packaging
  • Solid revenue and profit growth guidance

Downsides

  • High P/E ratio relative to peers
  • Low dividend yield
  • Dependence on pharma spending cycles

Timeline

  • 2021: 2-for-1 stock split (West Pharma IR)
  • 2023: UBS raised price target to $324 (Reuters)
  • 2026: Stock trading near $336.39; average target $343 (MarketBeat)

Clarity

Confirmed facts

  • Current price $336.39 (as of June 23, 2026) – MarketBeat
  • 2-for-1 stock split executed in 2021 – West Pharma IR

What’s unclear

  • Future stock price direction due to market volatility
  • Potential impact of regulatory changes on pharmaceutical packaging demand
  • Analyst target price of $343 from Yahoo Finance (varies across platforms)

Quotes

The demand for drug components remains robust, and West Pharma is well-positioned to capitalize on that.

— UBS analyst, after raising price target to $324 in Feb 2023 (Reuters)

WST is rated a Buy, with a consensus target of $343, reflecting upside potential from current levels.

— Yahoo Finance consensus (MarketBeat)

For investors considering West Pharma, the choice is between a growth story with strong analyst backing and a premium valuation that leaves little room for error. The coming quarters will test whether its guidance holds, but for now the momentum is clearly on the side of the bulls.

Additional sources

youtube.com, financhill.com, lightyear.com, marketscreener.com

Don't miss these

Frequently asked questions

What is the dividend yield of West Pharma stock?

The dividend yield is approximately 0.6%.

How often does West Pharma pay dividends?

West Pharma pays dividends quarterly.

What is the market capitalization of West Pharmaceutical Services?

It is approximately $25 billion.

Who are West Pharma’s main competitors?

Key competitors include AptarGroup, Berry Global, and Gerresheimer.

How can I buy West Pharma shares?

Shares are traded on the NYSE under ticker WST through any brokerage account.

What is the 52-week high and low for WST?

The 52-week range is $280 (low) to $360 (high).

Is West Pharma overvalued based on its P/E ratio?

With a P/E of ~35, it trades at a premium compared to the broader market, but growth potential justifies this for many analysts.